How can biotech companies prepare for security audits, investors, and due diligence?
Biotech companies secure lab systems and research environments through network segmentation, access controls, endpoint protection, monitoring, backup strategies, and governance processes designed for scientific operations. Effective protection reduces cyber risk while supporting research continuity, regulatory obligations, and intellectual property protection.
Table of contents
Why do lab systems require specialized security controls?
Laboratory environments differ from traditional business networks because they contain scientific instruments, research platforms, sensitive datasets, and specialized applications that directly support discovery and development activities.
Common challenges include:
- Legacy operating systems
- Instrument-connected workstations
- Third-party vendor access
- Research data repositories
- Specialized laboratory software
- Limited maintenance windows
Many scientific systems cannot be secured using standard enterprise approaches. Organizations that account for operational requirements and scientific workflows create stronger protection without disrupting research activities.
What systems should biotech companies prioritize for protection?
Security programs should focus on assets that support research, data management, and laboratory operations. High-priority systems include:
- LIMS platforms
- ELN environments
- Research databases
- Instrument control systems
- Laboratory workstations
- File storage repositories
- Identity management platforms
- Cloud collaboration tools
The table below summarizes common priorities.
System type | Primary risk | Security focus |
LIMS | Data manipulation | Access controls |
ELN platforms | Unauthorized access | Identity security |
Laboratory workstations | Malware infection | Endpoint protection |
Scientific instruments | Legacy vulnerabilities | Network segmentation |
Research repositories | Data theft | Monitoring and auditing |
Cloud platforms | Account compromise | Access governance |
Prioritizing critical assets helps security teams focus resources where operational and business risks are greatest.
What should be included in a biotech cybersecurity risk assessment?
A biotech cybersecurity risk assessment should evaluate the systems, data, users, and processes that support research, laboratory operations, compliance activities, and business functions. The goal is to identify vulnerabilities, assess potential business impact, and prioritize risk reduction efforts.
Key assessment areas include:
- Laboratory information management systems (LIMS)
- Electronic laboratory notebooks (ELN)
- Research data repositories
- Cloud applications
- Identity and access management
- Endpoint security
- Third-party relationships
- Backup and recovery capabilities
Organizations that regularly assess risk gain greater visibility into security gaps and can prioritize resources based on operational and business impact.
How often should biotech companies perform security assessments?
Biotech companies should conduct cybersecurity assessments at least annually and whenever significant changes in technology, operations, regulations, or business occur. Additional reviews are frequently appropriate after cloud migrations, acquisitions, major infrastructure changes, or security incidents.
Common assessment triggers include:
- Annual risk reviews
- New research initiatives
- Regulatory audits
- Technology deployments
- Third-party onboarding
- Security incidents
Regular assessments help identify emerging risks before they affect research activities, compliance requirements, or intellectual property.
How can biotech companies secure LIMS, ELN, and research data platforms?
LIMS, ELN, and research management systems require layered safeguards because they frequently contain valuable intellectual property and regulated records.
Important controls include:
- Multi-factor authentication
- Role-based permissions
- Activity monitoring
- Audit trail retention
- Encryption controls
- Backup validation
Special attention should be given to systems supporting clinical research, quality management, sample tracking, and electronic records. Security teams should regularly review user privileges and remove unnecessary access. Security providers, such as Single Point of Contact, frequently help biotech organizations evaluate access governance and monitoring practices across research applications. Stronger oversight reduces the likelihood of unauthorized activity affecting scientific data or regulatory records.
How can biotech companies secure laboratory workstations and connected instruments?
Laboratory workstations often support instruments that cannot tolerate frequent software changes or aggressive security controls.
Effective approaches include:
- Isolating instrument networks
- Restricting internet access
- Limiting administrative privileges
- Monitoring device activity
- Applying approved updates
- Controlling removable media
Many scientific instruments remain in operation for years after deployment. Additional safeguards around those systems reduce exposure while preserving operational stability. Balancing protection with laboratory productivity supports both cybersecurity objectives and scientific output.
How does network segmentation improve lab security?
Network segmentation improves lab security by isolating critical systems and reducing opportunities for attackers to move between research, laboratory, and business environments. Common segmentation strategies include:
- Separating laboratory networks
- Isolating research repositories
- Restricting vendor connections
- Limiting instrument communications
- Controlling privileged access
- Filtering network traffic
Providers, such as Single Point of Contact, often assist organizations with network architecture reviews that identify opportunities to reduce unnecessary connectivity between critical assets. Reducing attack pathways helps contain security incidents and minimizes disruption across scientific environments.
How can biotech companies detect threats across laboratory environments?
Laboratory operations benefit from continuous visibility across users, endpoints, applications, and network activity. Monitoring activities commonly include:
- User behavior analysis
- Endpoint event collection
- Network traffic analysis
- Access review processes
- Security alert investigation
- Threat detection workflows
Security operations teams frequently focus on identifying unusual behavior involving research data, laboratory systems, cloud platforms, and privileged accounts. Earlier identification of suspicious activity improves response capabilities and reduces the likelihood of significant operational disruption.
How can biotech companies support compliance requirements in laboratory environments?
Laboratory systems frequently support regulated activities that require documentation, traceability, and oversight.
Security controls commonly support:
- FDA 21 CFR Part 11 requirements
- HIPAA obligations
- GxP initiatives
- Sponsor security reviews
- Audit readiness programs
- Risk management activities
Biotech companies should maintain records demonstrating how systems are monitored, accessed, maintained, and protected. Service providers, such as Single Point of Contact, help biotech organizations establish reporting and documentation practices that support regulatory reviews. Well-maintained records improve confidence during audits and assessments.
How can a biotech prepare for a HIPAA security risk assessment?
Biotech organizations preparing for a HIPAA security risk assessment should begin by identifying where protected health information (PHI) is stored, processed, transmitted, or accessed. Preparation efforts should focus on evaluating controls, documenting risks, and validating compliance with HIPAA Security Rule requirements.
Preparation activities commonly include:
- Inventorying systems containing PHI
- Reviewing access controls
- Evaluating audit logging
- Assessing vulnerability management practices
- Reviewing incident response procedures
- Testing backup and recovery processes
Organizations that maintain current documentation and routinely evaluate security controls are generally better prepared for HIPAA assessments and related audits.
How do we reduce security risk before an FDA, HIPAA, or investor review?
Organizations reduce security risk before external reviews by addressing known vulnerabilities, validating security controls, strengthening documentation, and demonstrating ongoing oversight of critical systems. Reviewers frequently focus on evidence that controls are functioning effectively rather than written policies alone.
Common preparation activities include:
- Completing risk assessments
- Remediating critical vulnerabilities
- Reviewing privileged access
- Testing incident response procedures
- Validating recovery capabilities
- Updating security documentation
Proactive preparation helps reduce surprises during audits, due diligence reviews, compliance assessments, and investor evaluations.
What security questions will investors ask a biotech during due diligence?
Investors increasingly evaluate cybersecurity as part of operational and financial risk management. Due diligence reviews frequently focus on how organizations identify, monitor, and mitigate cybersecurity risks that could affect valuation, research continuity, or commercialization efforts.
Common questions include:
- Has the company completed a recent cybersecurity assessment?
- How are research assets protected?
- What monitoring capabilities are in place?
- Has the organization experienced prior security incidents?
- What compliance requirements apply to operations?
- How are third-party risks managed?
- What business continuity plans exist?
Organizations that can provide documented evidence of security governance, monitoring, and risk management are often better positioned during investor evaluations.
How can biotech companies protect research data in cloud environments?
Biotech companies protect research data in cloud environments through access governance, identity controls, activity monitoring, and secure data-sharing practices. At the same time, it has increased the importance of access governance and configuration management.
Key safeguards include:
- Identity management controls
- Privileged access reviews
- Cloud activity monitoring
- Secure file sharing
- Data classification policies
- Configuration assessments
Cloud platforms frequently contain research collaborations, sponsor communications, study documentation, and proprietary datasets that require additional oversight.
Organizations should understand where research information resides, who can access it, and how activity is monitored. Strong governance reduces the likelihood of accidental exposure or unauthorized disclosure.
How should biotech companies prepare for security incidents affecting lab systems?
Incident response planning should address both cybersecurity and operational considerations. Preparation activities include:
- Asset inventory development
- Escalation procedure documentation
- Backup testing programs
- Recovery plan validation
- Communication planning
- Response exercise execution
Scientific operations may require additional recovery considerations compared to standard business systems. Providers, such as Single Point of Contact, often support tabletop exercises and preparedness reviews that help identify process gaps before an incident occurs.
Organizations with documented response procedures generally recover more efficiently during disruptions.
How can a small biotech company become audit-ready without overbuilding security?
Small biotech companies can improve audit readiness by focusing on foundational controls that address the highest-priority risks rather than implementing enterprise-scale security programs prematurely. A risk-based approach helps align investments with organizational size, regulatory obligations, and operational complexity.
Priority areas typically include:
- Multi-factor authentication
- Endpoint protection
- Access management
- Security awareness training
- Backup and recovery processes
- Vulnerability management
- Incident response planning
Organizations that establish strong fundamentals can support compliance objectives, improve audit readiness, and demonstrate responsible risk management without creating unnecessary operational overhead.
Strengthening security across biotech research environments
Securing lab systems requires more than traditional IT security controls. Effective programs combine access governance, segmentation, monitoring, endpoint protection, cloud security, and compliance support to address the unique requirements of scientific operations. Organizations that align security practices with research workflows are better positioned to protect intellectual property, maintain regulatory readiness, and support long-term innovation.
Where can biotech companies learn more about managed security providers?
Organizations can learn how managed security services support biotech environments through Single Point of Contact’s biotech IT and security services. Services include 24×7 monitoring, threat detection, incident response, compliance support, Microsoft 365 security, and protection of research data and intellectual property.
Related Articles
How can biotech companies secure lab systems and research environments?
Laboratory systems contain valuable intellectual property, research data, and specialized scientific infrastructure. Learn how biotech organizations secure LIMS, ELN platforms, laboratory instruments, cloud applications, remote researchers, and research environments while supporting operational continuity and regulatory obligations.
Biotech managed security resource center
This hub provides an overview of biotech cybersecurity, including managed security services, MDR, managed SOC, security operations maturity, intellectual property protection, ransomware preparedness, compliance requirements, audit readiness, vendor risk management, and strategies for securing research environments.
Biotech cybersecurity services overview
This page provides an overview of cybersecurity, compliance, cloud, and managed IT services for biotech companies. Learn how life sciences organizations protect research data, support laboratory environments, strengthen operational resilience, meet regulatory requirements, and align technology strategies with scientific and business objectives.
Text
Frequently asked questions
Text
About the author
Gregory Morawietz is a technology executive with experience evaluating and comparing IT and security service models. He helps organizations understand trade-offs among delivery models in terms of cost, scalability, and operational impact. His work includes supporting organizations in regulated industries such as life sciences, healthcare, and technology. Gregory brings a structured, practical perspective to the comparison of technologies and service models in a complex and evolving landscape.